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Abstract
Chimeric viruses constructed between a highly pathogenic Feline Immunodeficiency Virus isolate (FIV-C36) and a less
pathogenic but neurotropic strain (FIV-PPR) have been used to map viral genetic determinants of in vivo pathogenicity.
Chimeric virus FIV-PCenv, which contains FIV-C36 genome from the 39 region of pol to upstream of the 39LTR on an FIV-PPR
backbone, was previously shown to be replication-competent in vivo, inducing altered CD4
+ T-cell and neutrophil profiles
intermediate between parental strains following a delay in viral replication during initial infection. Examination of FIV-PCenv
proviral sequences recovered at week 11 post-infection revealed two changes compared to initial viral inoculum; the most
significant being arginine to histidine in the integrase region of Pol at residue 813 (R813H). Pooled plasma from the initial in
vivo study was used to inoculate a second cohort of cats to determine whether similar virulence and kinetics could be
established following primary infection. Viral replication kinetics and immunocyte profiles were monitored in blood, bone
marrow, and saliva over a one-year period. Passaged FIV-PCenv again displayed intermediate phenotype between parental
strains, but unlike primary experiments, the onset of acute viremia was not delayed. CD4/8 alterations were noted in all
groups of animals, though significant changes from controls were delayed in FIV-PPR infected animals compared to FIV-C36
and FIV-PCenv. In vivo passage of FIV-PCenv increased replication-competence relative to the initial molecularly-cloned
chimera in association with one adaptive nucleotide change in the 59 end of the genome relative to primary tissue culture
inoculum, while mutations in the 39 end of the genome were not detected. The results are consistent with the interpretation
that 39 elements contribute to heightened virulence of FIV-C36, and that integrase residue 813 plays an important role in
facilitating successful in vivo replication.
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Introduction
Feline immunodeficiency virus (FIV) is a naturally-occurring
lentivirus of domestic cats. Infection results in acquired immuno-
deficiency syndrome associated with progressive loss of CD4
+ T-
lymphocytes [1,2,3,4,5,6]. FIV has a similar genome structure as
human immunodeficiency virus (HIV) [7], containing several
open-reading-frame (ORF) accessory genes [8,9], and also uses a
two-receptor mechanism, with cellular entry via CXCR4
chemokine receptor [10,11,12,13]. Similarities between these
complex lentiviruses make FIV infections a relevant animal model
for studies of HIV-AIDS [14,15].
Five FIV clades (A–E) have been identified and are distinguished
by envelope sequence [16,17,18,19,20,21]. Two isolates, FIV-PPR
and FIV-CPG (molecular clone FIV-C36), belonging to clades A
and C, respectively, are variable with regard to disease potential
[4,22,23]. Pathology of lentivirus subtypes can be attributed to any
number of properties, including replication rates or levels dictated
by a combination of viral and host factors; these include viral
genome secondary structure, efficacy of evasion of a host innate or
adaptive immune response, bindingaffinity to cell surface receptors,
and epigenetic factors. While it is probable that host innate and
adaptive immune responses relating to host genotype contribute to
these differences, pathology of FIV-C36 and molecularly-cloned
FIV-PPR is predictable from study to study [6,23,24]. Chimeric
viruses constructed between these two phenotypically distinct strains
of FIV are potentially useful tools to identify viral molecular
determinants of virulence and/or differences in viral tropism or
kinetics. Several chimeric constructs were therefore developed by
exchanging elements between FIV-C36 and FIV-PPR as previously
reported and reviewed in Figure 1 [24].
Initial in vivo studies demonstrated that FIV-PC39LTR (FIV-
C36 rev2 and 39 LTR on the FIV-PPR backbone) was infectious,
although attenuated compared to parental constructs. In contrast,
FIV-PCenv displayed a phenotype intermediate to parental viruses
with regard to plasma viremia, proviral load, and CD4
+ T-cell and
neutrophil declines. This construct includes FIV-C36 vif, orfA, env,
and the first exon of rev on the FIV-PPR backbone; approximately
250 nucleotides of 39 FIV-C36 pol are also included, resulting in a
chimeric integrase protein. Interestingly, FIV-PCenv peak viral
load and development of clinical disease was delayed by three
weeks compared to FIV-PPR, FIV-PC39LTR, and FIV-C36,
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that (1) FIV-C36 genomic elements represented in FIV-PCenv are
related to pathogenicity, and (2) infection with primary FIV-
PCenv may have resulted in accumulation of mutations leading to
enhanced replication capacity following an initial delay. Increases
in pathogenicity of HIV/SIV (SHIV) chimeras have been reported
during ex vivo [25,26] and in vivo passages in macaques [27].
Further, quasispecies diversity with respect to receptor usage and
host-cell range are broadened upon viral passage [28], supporting
the hypothesis that FIV-PCenv was similarly affected.
We investigated whether delayed pathogenicity of FIV-PCenv
was an inherent phenotype of its manipulated genome, or if
elements near the env region contribute to enhanced virulence after
a period of adaptation. To test the hypothesis that FIV-PCenv
acquired mutations during primary infections, we performed
sequence analysis of proviral DNA from an FIV-PCenv infected
cat during peak viremia. In addition, a second cohort of domestic
cats was inoculated with pooled plasma from the primary FIV-
PCenv and parental strain infections to evaluate the impact of
serial passage on viral replication kinetics and pathogenicity. In
this year-long in vivo analysis, peripheral and bone marrow viral
kinetics, immunopathogenicity, and viral salivary excretion were
evaluated. While no extensive nucleotide substitutions were
detected in the 39 end of the chimeric genome following in vivo
passage, two nucleotide changes were detected during compari-
sons of in vitro inoculum and in vivo derived sequences in the 59 half
of FIV-PCenv. A silent TRC mutation was found at amino acid
64 of Gag, resulting in an ATTRATC codon change in
isoleucine. A more significant change was an arginine to histidine
substitution at residue 813 (R813H) within the integrase region of
pol. This residue has been reported as a cysteine in parental FIV-
PPR (and was verified as such in this study) as well as all other
domestic FIV sequences; however, variations occur amongst the
non-domestic FIVs and the homologous site in HIV-1 integrase
(Figure 2). Thus, a substitution of Cys.Arg apparently occurred
during in vitro propagation. Secondary in vivo passage of chimeric
virus using plasma from primary infections, during which a further
mutation of Arg 813 to His occurred, resulted in more rapid viral
kinetics compared to parental strains. FIV-PCenv viremia in bone
marrow, plasma, and saliva ultimately plateaued in the same range
observed in cats infected with FIV-C36, surpassing FIV-PPR
levels. FIV-PCenv plasma RNA along with PBMC and bone
marrow proviral levels were elevated during serial passage when
compared to primary infection, an effect not observed in cats
infected with parental viruses. Further analysis of site 813 in
proviral and plasma isolates from all cats in the primary passage
indicated nonsynonymous mutations at this site in 4/5 cats relative
to viral inoculate (2 animals with R813H and 2 with R813C). All 5
cats in the secondary passage had a His residue at this site,
consistent with the predominant plasma viral quasispecies in the
2
nd passage inoculum. These findings suggest that: (1) serial
passage with a chimeric virus containing 39 elements of virulent
FIV-C36 confers enhanced replication capacity to FIV-PPR in
both peripheral and parenteral compartments; and, (2) changes in
replication rates in vivo between the primary and secondary
passages were a consequence of a mutation at residue 813 of
integrase. Since the chimeric virus included portions of 39 pol from
FIV-PPR and FIV-C36, this may represent a requirement for
coordination of this residue with components of the C-terminus of
the integrase protein.
Results
FIV-PCenv sequence analysis
We chose the time point at which group mean levels during
primary infection were highest (day 77 PI) for amplification and
analysis of provirus from an FIV-PCenv infected cat [24]. This
sample was chosen because the likelihood of detecting nucleotide
differences compared to inoculum would be greatest after the
initial lag period displayed by the chimera. Complete proviral
sequence was characterized from Cat# FIV-PCenv-1 at a
timepoint when 1.68610
4 FIV proviral equivalents per million
PBMC was detected. Consensus sequence of six clones per region
amplified was aligned with that of virus stock sequenced using
identical methods.
Two changes were observed between provirus obtained from
Cat # FIV-PCenv-1 and FIV-PCenv stock. First, a silent TRC
mutation was found at amino acid 64 of Gag, resulting in an
ATTRATC codon change in isoleucine. Second, a mutation at
amino acid 813 of Pol resulted in a codon change from CGT
(arginine) in inoculum to CAT (histidine) in Cat # FIV-PCenv-1
(R813H; Figure 2). Original FIV isolates PPR and C36, as well as
two other FIV isolates (clade A isolate Petaluma and defective Felis
catus strain reported in GenBank), have cysteine at this position,
which falls within the integrase region of Pol; sequence analysis
verified that the molecular clone of FIV-PPR used to generate
FIV-PCenv contained Cys at this site. Alignment with nondomes-
tic FIV and HIV sequences demonstrates divergence at this
residue among more distantly related FIVs (Figure 2). To
Figure 1. Clade A/C FIV chimeras. Clade C FIV-C36 sequences are depicted in black, and clade A FIV-PPR sequences in white. Recombinant clone
FIV-PCenv was generated by exchanging ,5 kb of FIV-C36 between the NdeI restriction endonuclease recognition sites. FIV-PC39LTR contains FIV-
C36 39LTR including the second exon of rev.
doi:10.1371/journal.pone.0024020.g001
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cats harbored this mutation in integrase, we directly sequenced
both integrated (days 102 and 156 PI) and circulating virus (day 77
PI), and found the same nonsynonomous mutation to His in a
second individual (FIV-PCenv-5), reversion to wild-type Cys in
two cats (FIV-PCenv-3 and 4), and sequence consistent with the
inoculum (Arg) in the remaining animal (FIV-PCenv-2; Table 1).
Figure 3 shows PBMC (A) and plasma (B) viral loads of individual
FIV-PCenv infected cats, in which a His mutation tended to
display higher viremia compared to Cys or Arg. Additionally, all
cats inoculated with pooled plasma from the first inoculation were
infected with virus containing the CAT His codon at the first
timepoint (day 21 PI) in which there was detectable viremia in all
individuals (Table 1).
In vivo passage of FIV-PCenv
To test if delayed viral loads noted during first round infections
of domestic cats [24] were indicative of an initial period of virus
adaptation that could be overcome with serial passage, pooled
plasma from infected cats was used as inoculum for second round
in vivo infections. Five cats per group were inoculated intravenously
with plasma containing either FIV-PCenv, FIV-C36, or FIV-PPR,
or naı ¨ve plasma at doses equalized as described in Methods.
Relative levels of viremia were then assessed over time by
measuring both the number of viral RNA copies per milliliter
plasma and the number of viral DNA copies detected per 10
6
PBMC DNA equivalents. Initial spikes of viral RNA copies/ml
occurred 17–21 days PI for all infection groups (Figure 4) and were
highest in FIV-C36, followed by FIV-PCenv, then FIV-PPR.
Circulating virus levels fluctuated for a period after this initial spike
for all groups, with most FIV-PPR values below the level of
detection until day 81 PI. In fact, two of five FIV-PPR infected
cats were aviremic for nearly six months, until day 173 PI.
Maximum mean levels of plasma viremia were detected between
three and five months PI for all groups, remaining relatively
constant until day 347 PI and were as follows (RNA copies/ml
plasma): FIV-PPR=5.68610
2, FIV-PCenv=2.58610
4, and FIV-
C36=2.26610
4 (Figure 4).
FIV-PCenv proviral kinetics in PBMC or bone marrow were
similar to circulating virus following in vivo passage. All animals
had detectable integrated proviral gag sequences in PBMCs on day
14 and values were approximately equivalent for all constructs on
day 17 (Figure 5A). After day 17, FIV-C36 values were highest,
with FIV-PCenv intermediate between FIV-C36 and FIV-PPR.
However, the integrated copy number for the chimeric virus
continued to rise and reached levels equivalent to FIV-C36 by day
180. Copy numbers for FIV-PPR also rose after an initial plateau
between days 20–50, but remained approximately 1 log lower then
FIV-C36 and FIV-PCenv throughout the experiment (Figure 5A).
Mean proviral copies/10
6 PBMCs were highest at 3 to 4 months
PI. These values remained relatively constant for all groups as
follows: FIV-PPR=2.4610
4, FIV-PCenv=1.14610
5, and FIV-
C36=3.55610
5 (Figure 5A).
Similar trends were also reflected in bone marrow proviral
loads, with FIV-PCenv levels remaining intermediate until time of
the last biopsies, when they were equal to those of FIV-C36
(Figure 5B). Two FIV-PPR cats had undetectable bone marrow
proviral FIV on day 17 PI; of these, one remained negative until
between days 35 and 55 PI. One FIV-PCenv cat had undetectable
bone marrow FIV at day 35 PI sampling (Table 2). Otherwise, all
bone marrow samples tested were positive. Compared to PBMC
levels, DNA copies/10
6 bone marrow cells were higher on day 173
and 260 PI (Figure 5B and Table 2), and mean values were higher
in FIV-PCenv than FIV-C36. Similar kinetics were noted in
salivary viral RNA excretion, as follows.
Saliva from FIV-PCenv infected animals was negative at time of
first sampling (day 28), but rose steadily thereafter, reaching
1.9610
4 copies/ml by day 67 PI (Figure S1). FIV-C36 saliva
viremia was higher than the chimera earlier in sampling, with
detectable levels of 2.5610
2 copies/ml at first sampling, and
Figure 2. Amino acid comparison of sequences from cat FIV-Pcenv-1 and virus inoculum with parental clones (PPR and C36),
another clade A domestic cat sequence (Petaluma), and nondomestic feline species (FIV-Oma=Pallas cat; FIV-Ple=lion; FIV-Pco-
puma). FIV-Fca defective isolate indicates replication-deficient strain from a domestic cat. Highlighted cysteines are conserved among domestic cat,
but variation is noted at this site between and among felid species, and in prototypic HIV-1 lab strain NL4-3. Initial viral inoculum had an arginine
incorporated at this site, which was replaced by histidine following infection of cat # FIV-PCenv-1.
doi:10.1371/journal.pone.0024020.g002
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integrated and circulating virus at days 102 and 156 post-inoculation detected polymorphism at Pol residue 813 (integrase).
doi:10.1371/journal.pone.0024020.g003
Table 1. Analysis of Phases I and II circulating and integrated FIV-PCenv integrase residue 813.
codon/aa
pFIV-PPR reference* TGT/Cys
pFIV-C36 reference* TGT/Cys
FIV-PCenv inoculum** CGT/Arg
FIV-PCenv-1 (d77)** CAT/His
Phase I d77 plasma d102 PBMC d156 PBMC
FIV-PCenv -1 CAT/His CAT/His CAT/His
FIV-PCenv -2 CGT/Arg CGT/Arg CGT/Arg
FIV-PCenv -3 TGT/Cys TGT/Cys TGT/Cys
FIV-PCenv -4 NA TGT/Cys TGT/Cys
FIV-PCenv -5 CAT/His CAT/His CAT/His
Phase II d21 plasma d21 PBMC
FIV-PCenv -6 CAT/His CAT/His
FIV-PCenv -7 CAT/His CAT/His
FIV-PCenv -8 CAT/His CAT/His
FIV-PCenv -9 CAT/His CAT/His
FIV-PCenv -10 CAT/His CAT/His
*sequence of parental plasmids used for cloning FIV-PCenv confirmed at TSRI.
**TOPO clones from full-genome sequencing of Phase I inoculum and one individual cat.
doi:10.1371/journal.pone.0024020.t001
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4 copies/ml by day 81 PI. Salivary viremia
tapered after these initial peaks in both groups of animals, then
increased again after day 120 PI, at which time FIV-PCenv levels
exceeded FIV-C36. At time of last sampling (day 173 PI), FIV-
PCenv mean saliva viremia was recorded as 6.31610
4 copies/ml,
nearly four times that of FIV-C36 (1.75610
4 copies/ml) (Figure
S1). Plasma and salivary viremia did not appear to be coordinated
over time for either virus.
Comparisons were made of the time course for onset of acute
viremia during primary infection versus results observed during
secondary viral passage (Figure 6). Along with rescued replication
kinetics from passage, FIV-PCenv PBMC proviral load was more
than one order of magnitude higher than levels exhibited during
primary infections described previously [24] in both PBMC
(Figure 6) and bone marrow (Figure 7). This trend was not
observed for FIV-C36 or FIV-PPR (Figure 6, 7). In contrast to
trends for proviral load, plasma viremia levels tended to be lower
for all three viruses during secondary infections (Figure 6). This is
particularly true during days 1–60 for FIV-PPR and FIV-C36.
Hematologic effects of passaged FIV-PCenv
Onset of decreases in CD4
+ T-lymphocyte relative to uninfected
controls was similar to primary infections during FIV-C36 and
FIV-PCenv infections; statistically significant differences between
infected cats and non-infected controls were observed starting on
days 17 and 63 PI, respectively, and persisted through day 138 PI
(Figure 8A). FIV-PPR passage also resulted in significant decreases
in CD4
+ T-cell count starting at day 95 PI and persisting through
day 138 PI. These declines were reflected in CD4:CD8 ratios
(Figure 8B).
Unlike initial infections, mean neutrophil counts for all infection
groups remained above 2000 cells/ml (the baseline for feline
neutropenia), with no significant differences when compared to
non-infected control cats (Figure 8C). Individual animals from all
infection groups and one negative control experienced intermittent
neutropenia at some timepoints. FIV-C36 infection in particular
resulted in neutropenia in three individuals starting at day 35 PI
and persisting until day 111 PI whereupon the same three cats
experienced intermittent neutropenia until day 259 PI (data not
shown).
Discussion
FIV infection of the domestic cat offers a model system for basic
biological research of lentivirus-induced immunodeficiencies,
along with development of treatments for HIV-AIDS. Two strains
of FIV, FIV-PPR and FIV-C36, have been molecularly cloned
and studied in relationship to severity of disease following
productive infection in multiple laboratories [6,23]. Higher viral
titers and more rapid onset of clinical symptoms are consistently
observed during experimental infections with FIV-C36 compared
to FIV-PPR. FIV-C36, a highly pathogenic molecular clone of the
clade C FIV isolate FIV-PGammar, differs in genetic sequence
from the clade A molecular clone FIV-PPR by approximately 15%
[6]. Therefore, it is rational to believe that infections of the
domestic cat with molecular chimeras between FIV strains
possessing differing pathogenic phenotypes can help identify
which genetic elements contribute to progression to AIDS.
Figure 4. Circulating virus during in vivo passage of clade A FIV-PPR, clade C FIV-C36, and A/C chimeric FIV-PCenv. Group means with
standard deviation for plasma viremia are shown as numbers of RNA copies/ml over the course of the study. PCR reactions were performed in
triplicate. Mock-infected cats had undetectable viremia (data not shown).
doi:10.1371/journal.pone.0024020.g004
Figure 5. PBMC (A) and bone marrow (B) proviral loads during
in vivo passage of FIV-PPR, FIV-C36, and FIV-PCenv. Group
means with standard deviation are shown as numbers of FIV gag
equivalents/10
6 cells over the course of the study. PCR reactions were
performed in triplicate. Mock-infected cats were provirus-negative (data
not shown).
doi:10.1371/journal.pone.0024020.g005
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pathology resulting from primary infections with FIV-PCenv, a
chimera containing the regulatory elements vif, orfA, rev1, and env
from a highly virulent clade C strain (FIV-C36) on the background
of a moderately virulent clade A strain (FIV-PPR). In preliminary
studies [24], FIV-PCenv viremia kinetics displayed a lag period
during the first month of infection, as well as a delay in classic
indicators of immunodeficiency as reflected in drops in CD4
+ T
cell and neutrophil counts compared to parental viruses.
Eventually, these parameters became intermediate to those of
parental viruses.
Many studies have demonstrated that chimeras generated in the
laboratory are typically less virulent than both parental clones
[24,29,30,31]. This is likely due to the fact that host innate and
adaptive immune responses are mounted against viral infection,
and successful isolates arise in the face of many factors designed to
limit viral success. Thus, chimeric viruses can be crippled since
portions of the virus have evolved independently, and adaptations
in one portion of a wild-type virus may overcome detrimental
mutations in another part of the genome. Therefore, it was striking
that FIV-PCenv was able to recover a phenotype intermediate to
parental viruses. Despite strong host immunity, a ‘‘diversity
threshold’’ model has been proposed in which viral variants with
beneficial mutations are able to persist and induce immunodefi-
ciency when the number of diverse quasispecies is high enough
[32]. This model has been supported by analysis of env evolution
during rapid, serial passage of SHIVs in macaques [33]. During in
vivo passage, the infecting virus pool has already overcome the
diversity threshold in previous hosts. Thus, upon subsequent
rounds of infection in naive hosts, there occurs faster onset of
clinical disease accompanied by rapid antibody response and high
viral loads [27]. The studies presented here sought to determine
whether FIV-PCenv passage supported this selection hypothesis.
We surmised that chimeric FIV-PCenv may have accumulated
mutations during the first-round of in vivo infection that allowed it
to display a replication profile intermediate to parental viruses by
day 77 PI. We hypothesized such changes would occur in the 39
portion of the genome and were required to coordinate function
between chimeric elements of the two parental viruses. However,
analysis of 4200 nucleotides from the 39 FIV-C36 half of the
genome revealed no mutations in 6 FIV genome sequences
compared to viral inoculum. Upon evaluation of the 59 FIV-PPR
half of the chimera, however, we identified an R813H Pol
mutation in proviral sequences compared to viral inoculum in 6
PCR-derived clones from one infected individual, and confirmed
by direct sequencing in another cat. Virus from the remaining
three cats retained Arg (n=1), or contained wild-type Cys (n=2),
as determined via direct sequencing of both integrated and
circulating FIV-PCenv. This site in integrase typically has a
conserved cysteine residue in domestic cat FIV, but varies in
nondomestic cat FIVs and HIV. This finding suggests that during
in vitro passage, a TRC mutation arose in the TGT codon for
cysteine in parental PPR leading to CGT (arginine) in the
inoculum. Following passage in two animals, a GRA mutation
was introduced, resulting in a replacement of arginine with
histidine (CAT). Virus containing cysteine that was recovered from
two cats may represent a minor population present in inoculum
undetected during sequencing of clones, or a reversion to wild-type
due to pressure at a mutation hot-spot. The fact that this site is not
occupied by cysteine in 3 nondomestic FIVs, or by homology,
HIV indicates that it is not conserved across all lentiviral genomes.
Change in a glutamic acid residue highly conserved among
lentivirus species, and positioned four amino acids upstream of Pol
C813 in FIV-PCenv (Figure 2, red highlight), confers resistance to
the integrase inhibitors raltegravir and elvitegravir [34]. Further,
FIV Pol C813 may be a component of secondary structural motifs
important for integrase function, as this region is part of alpha-
helix-1 in HIV [35], along with SIV [36], primate foamy virus
[37], and Rous sarcoma virus [38] integrases. In addition to being
proximal to a potential target for drug-resistance mutations, a
panel of synthetic peptides containing the HIV homologue to FIV
Pol C813 (HIV Pol E811) were shown to stimulate IFN-c
production from CD8
+ T cells [39]. Together, these reports
suggest that this area of integrase is conformation flexible, and
Table 2. PBMC and bone marrow mean proviral loads.
day 17 PI day 35 PI
PBMC BM # cats BM+ PBMC BM # cats BM+
FIV-PPR 2.02E+03 3.21E+01 3/5 1.72E+02 8.01E+02 4/5
FIV-PCenv 2.52E+03 5.48E+01 5/5 2.27E+03 9.03E+02 4/5
FIV-C36 7.85E+04 9.27E+03 5/5 3.36E+04 9.13E+04 5/5
day 55 PI day 95 PI
PBMC BM # cats BM+ PBMC BM # cats BM+
FIV-PPR 1.81E+03 3.05E+03 5/5 2.40E+04 4.30E+02 5/5
FIV-PCenv 1.19E+04 2.56E+04 5/5 9.94E+04 4.25E+03 5/5
FIV-C36 1.03E+05 2.09E+05 5/5 2.43E+05 7.78E+04 5/5
day 173 PI* day 260 PI*
PBMC BM # cats BM+ PBMC BM # cats BM+
FIV-PPR 1.96E+03 4.52E+03 4/4 5.27E+03 7.95E+03 4/4
FIV-PCenv 1.61E+04 5.28E+04 4/4 4.44E+04 1.12E+05 4/4
FIV-C36 1.51E+04 4.00E+04 4/4 3.63E+04 7.29E+04 3/3
*One cat each from FIV-C36 and FIV-PPR groups were euthanized early due to severe allergies, while 4/5 samples were obtained from FIV-PCenv group on days 173 and
260 PI, and 3/4 from FIV-C36 group on day 260 PI, explaining lower number tested.
doi:10.1371/journal.pone.0024020.t002
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response; our findings here would be consistent with escape from
immunological pressure. Additional studies will determine if CTL
haplotypes in PBMC from FIV-PCenv infected cats matches
peptides containing Pol 813.
It is interesting that we observed nonsynonomous mutations
at site Pol 813 in four of five animals following the apparent
initial nonsynonomous mutation which occurred in viral
inoculum. This would suggest this residue was under significant
mutational pressure both in vitro and in vivo, and likely accounts
for the delayed replication kinetics noted during initial viral
infection. Indeed, animals harboring either an Arg or His
mutation had higher viral loads th a nc a t si nw h i c hw i l d - t y p eC y s
was detected (Figure 3). Because FIV-PCenv contains approx-
imately 200 residues of FIV-PPR integrase, with the remaining
80 residues from FIV-C36, it is possible that important
interactions occur between res i d u e8 1 3( o c c u r r i n gi nt h eF I V -
PPR portion of the genome) and residues/structural compo-
nents of the terminal ,30% of the protein. Evaluation of
genomes rescued from cats infected with passaged virus, in
which the R813H substitution was uniformly found, supports
this hypothesis, and suggests that (1) delayed viral replication
kinetics during primary infection resulted from R813H,
restoring replicative capacity following in vitro mutation, and
(2) FIV-PCenv virulence results from 39 elements of FIV-C36
which were not measurably altered during in vivo passage. Since
pooled plasma from the first group of animals was used as
material for viral passage, and Cat# FIV-PCenv-1 had the
highest viremia, it is not surprising that we detected this strain in
all animals from the second group. What is noteworthy;
however, is the fact that R813H may have played a mechanistic
role in the rescue of replication kinetics. It would be interesting
Figure 6. Comparative replication kinetics of primary (dashed lines) viral infection versus passaged (solid lines) FIV-PPR, FIV-
PCenv, and FIV-C36. Proviral loads recorded as gag equivalents/10
6 cells are depicted in green, and circulating virus as RNA genomes/ml in orange.
Red arrows mark the delay in onset of acute viremia in primary versus secondary FIV-PCenv infections.
doi:10.1371/journal.pone.0024020.g006
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lines) FIV-PPR, FIV-PCenv, and FIV-C36. Proviral loads recorded as gag equivalents/10
6 cells. Red arrows mark the delay in onset of acute viremia
in primary versus secondary FIV-PCenv infections.
doi:10.1371/journal.pone.0024020.g007
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e24020to evaluate whether genomic substitution restoring the original
FIV-PPR sequence at this site (H813C) would additionally
enhance FIV-PCenv virulence, and may explain the observation
of cysteine at this site in two cats from the first study.
While plasma viremia in FIV-PCenv cats mirrored that of FIV-
C36 following primary infection, proviral copy numbers in PBMC
or bone marrow of cats infected with the chimera never reached the
values of FIV-C36 [24]. However, in vivo passage of FIV-PCenv
resulted in viral RNA and DNA copy numbers equal to those
measured for passaged FIV-C36 by day 81 post-inoculation both
peripherally and in bone marrow and saliva (Figures 6, 7, S1).
Moreover, FIV-PCenv proviral loads were one order of magnitude
higher upon passage, suggesting that either the initial replication-
competent FIV-PCenv inoculum dose was higher for second round
infections, or that progressive replication enhancement continued
during viral passage.
Figure 8. Timecourse of hematologic changes in domestic cats infected with passaged FIV-PPR, PC-env, and C36. Blood was sampled
at various time points over the course of infection. Complete blood counts, differential leukocyte analysis, and CD4
+ and CD8
+ T-lymphocyte
percentages in virus-inoculated cats (n=5/group), or sham-inoculated control cats (n=5) were calculated. CD4 counts (shown as number of cells/ml)
(A), CD4:CD8 ratios (B), and neutrophil counts (shown as cells/ml) (C) are demonstrated over the course of the study. For ease of viewing, error bars are
shown for control group only. Statistically significant values relative to normal control values are indicated by asterisks in same colors used for each
viral group (*, P between 0.01 and 0.05; **, P,0.01).
doi:10.1371/journal.pone.0024020.g008
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primarily passaged FIV-PPR- and FIV-C36-containing plasma is
unknown. Primary inoculations were composed of tissue culture
supernatant whereas the secondary challenge utilized pooled
plasma from cats. It is possible that plasma factors inhibited initial
viral replication, or that quasispecies transmitted had lower viral
replication rates. Plasma inoculum was normalized to equalize
viral input based upon real-time PCR measurements of particles/
ml. Because peak viral load during initial inoculation occurred
earlier during FIV-PPR and FIV-C36 infection (day 14 versus day
35 for FIV-PCenv), inoculums were prepared during different
stages of infection. Because FIV-PCenv peak plasma viremia was
lowest during primary inoculation, FIV-PPR and FIV-C36
inocula were diluted with naı ¨ve pre-inoculation plasma from the
same cats, whereas FIV-PCenv plasma was used undiluted. It is
possible these variations in inocula resulted in inaccuracies in
exposure, or presence of quasispecies with differing virulence
characteristics.
Although neutropenia was observed in three FIV-C36 cats
between days 35 and 259 PI, mean neutrophil levels never
significantly varied from those of mock-infected controls. This may
have related to the fact that control cats had low neutrophil counts
at seven time points; factors such as cage environment, allergies, or
stress can contribute to variability in hematology parameters [40].
One FIV-PCenv cat also experienced neutropenia from day 46–95
PI, and two different FIV-PPR cats experienced neutropenia on
days 3 and 173 PI, respectively. None of these effects, however,
resembled the marked neutropenia observed during first-round
infections with FIV-C36 or FIV-PCenv. The more dramatic
neutrophil declines observed during primary infections with FIV-
C36 and FIV-PCenv may be related to factors associated with use
of a biological inoculum (pooled plasma), or the fact that the
inoculum contained more varied viral quasispecies, and parallels
the observed lower plasma viremia established in this experiment.
Similar to primary infections, CD4
+ T-cell declines were
observed starting on day 17 PI in FIV-C36 cats which persisted
until day 138 PI. Statistically significant differences in CD4
+ T-cell
counts of the FIV-PCenv group compared to controls began on
day 63 PI. Previous infections with this chimera resulted in a
rebound in CD4 levels compared to controls. Conversely, during
second-round infection, P values remained below 0.01 through
day 138 PI. The FIV-PPR group also had significant differences
compared to controls between days 95 and 138 PI, strengthening
the hypothesis that viral passage results in enhanced virulence.
In this study we were able to evaluate distribution of proviral
DNA in bone marrow and compare viral RNA load obtained from
saliva with plasma viremia. These measures re-iterated kinetics
noted peripherally; namely, FIV-C36 initially peaked at loads
above FIV-PPR and the chimeric construct, but after approxi-
mately 81 days PI, FIV-PCenv levels exceeded those of parental
viruses. Because receptor-viral interactions are mediated by 39 env
determinants represented by FIV-C36 in the chimeric virus, we
reasoned that the distributions of the viruses might vary if Env
tropism dictated differential cell susceptibilities. The data gener-
ated in this study would suggest that replication competency and
virus shedding in saliva is more related to overall replicative
capacity versus Env-restricted tissue targeting, though a role for
enhanced replication in circulating cells of the bone marrow or
lymphoreticular system conferred by the 39 end of FIV-C36
cannot be discounted by this study.
The findings presented here indicate a role for FIV-C36
elements in FIV-PCenv pathogenesis compared to FIV-PPR
infections. To determine whether a particular genomic element is
responsible for the heightened virulence of FIV-C36 versus bulk 39
viral genomic substitution, it will be necessary to perform
infections using chimeras with single 39 FIV-C36 genes on the
FIV-PPR background. Experiments with replication-competent
FIV accessory-gene chimeras in which smaller regions of the
genome have been substituted would provide more insight into
specific genetic factors that influence viral replication rates and
virulence. Perhaps the most interesting finding reported here is the
association of enhanced replicative capacity in vivo with rescue of a
mutation which apparently arose during in vitro replication. This
study would suggest that residue 813 in FIV Pol is essential in
conferring in vivo replication, but is apparently not essential for in
vitro replication. Enhanced pathogenicity of chimera FIV-PCenv
relative to parental strain FIV-PPR that was independent of
mutations in 39 FIV-C36 elements suggests that env and 39
regulatory elements in FIV determine strain-dependent pathoge-
nicity.
Materials and Methods
Ethics Statement
This study was approved by the Colorado State University
Institutional Animal Care and Use Committee, ‘‘Molecular
Analysis of a Highly Pathogenic FIV’’, 07-125A. Colorado State
University’s animal care program is licensed by the USDA,
accredited by AAALAC, Intl, and holds an OLAW assurance
(A3572-01).
Cloning and analysis of FIV-PCenv sequences
FIV-PCenv stock was used as previously described [24] to infect
Cat#s FIV-PCenv-1 through 5 both orally and intravenously with
10
3.5 TCID50 particles/ml total (0.5 ml each route). Genomic
DNA was extracted from PBMCs purified on a Histopaque-1077
(Sigma) gradient. For whole genome sequencing, day 77 PI from
Cat# FIV-PCenv-1 was chosen as it represented the highest FIV-
PCenv proviral load attained during the study (1.68610
4) [24]. It
was reasoned that the greatest likelihood of detecting nucleotide
differences compared to inoculum would be in this sample. Cells
were washed and pellets frozen at 220uC overnight. DNA was
isolated using a DNeasy Tissue Kit (Qiagen). PCR conditions were
30 cycles of denaturation at 94uC for 1 min, annealing at 57uC for
30 s, and extension at 71uC for 1 min. Primer sequences were as
follows:
fA.1=CCGAACAGGGACTTGAGAAAG,
rA.1=TGGTGCAAATCTTGCTTCTG,
fA.2=CACCTACTGACATGGCCACA,
rA.2=GGTGAGGTAGTCCCAACTG,
fA.3=AAGTGGAAAATGGAGGATGC,
rA.3=CTTCTTGCCAGATTCCTTCC,
fA.4=AGAAGGCGGAAATACAAGCA,
rA.4=TCTTCACTCATCCCCTTCAG,
fC.1=GGGTAGAATAGGGGGAATGG,
rC.1=GCCTTACCTTGTCCTGCATA,
fC.2=CCAGAAGAGGCAGAGGAATT,
rC.2=CTGTTCCTGCTCCTGCAATG,
fC.3=CAACAGATTGGGGTTACATG, and
rC.3=TGAGTCATGTTCAGCTGTTTCC.
Products were separated on an agarose gel containing ethidium
bromide, excised, and purified using the QIAquick gel extraction
and purification kit (Qiagen). We used TA cloning with pPCR2.1
vector (Invitrogen) to propagate FIV-PCenv sequences in Top10
E. coli. Colonies were screened via restriction enzyme and PCR
Pathogenicity of FIV Linked to 39 Elements
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Viral inoculum was similarly amplified and evaluated; cDNA was
generated using RNA purified from FIV-PCenv viral stock
(QIAamp Viral RNA Mini Kit, Qiagen) as template in reactions
with SuperscriptII (Invitrogen) reverse transcriptase. Consensus
sequence was obtained from six-eight clones per region amplified.
Direct sequencing of genomic DNA and viral cDNA for all Phases
I and II individuals was performed with reverse primer
TCCAAGGAGGTTGTTTCAGG on gel purified templates
amplified via nested PCR with outer primers fA.4/rA.4 and
inner primers fA.4-2=CAAGATGGTGGCAGAAGAGA/rA.4-2=
GGCCATCCCTCCTATTCTA. Sequencing was performed at
TSRI Center for Nucleic Acid Research (TOPO clones C36 region)
and The University of Nebraska’s Center for Virology (TOPO clones
PPR region and all direct sequencing). Nucleotide and amino acid
alignments were analyzed with Sequencher
TM (Gene Codes Corpo-
ration, Ann Arbor, MI) and VectorNTI (Invitrogen).
In vivo infections
Twenty 14–16 week-old, SPF cats were housed in gang rooms
in AAALAC-international accredited CSU animal facilities
following protocols approved by CSU ACUC. Three groups
(n=5) of unanesthetized cats were inoculated intravenously with
1 ml pooled plasma from five cats previously infected with either
FIV-PPR, FIV-PCenv, or FIV-C36. Plasma from time point of
peak viremia for each virus (day 14 post-infection for FIV-PPR
and FIV-C36; day 35 for FIV-PCenv, based on RT-PCR values)
was normalized using pre-inoculation naı ¨ve plasma from matched
animals so that all animals received an equal number of viral
particles (1.38610
4). Five cats were administered naı ¨ve plasma and
used as non-infected controls. Animals were monitored daily for
clinical signs of illness throughout the study, and physical exams
were performed at blood collection. Weight measurements and
blood collections were performed on days 27, 3, 7, 10, 14, 17, 21,
28, 35, 46, 55, 67, 81, 95, 111, 138, 173, 216, and 259 PI for
detection of circulating virus and PBMC provirus, along with
hematologic analysis described below. One cat from each FIV-
PPR and FIV-C36 groups were euthanized early prior to day 173
PI due to obvious allergic dermatitis apparently unrelated to FIV
infection. Bone marrow samples were collected from the humerus
following ketamine/acepromazine/burtorphanol anesthesia on
days 3, 17, 35, 55, 95, 173, and 260 PI and were analyzed for
provirus.
Hematologic analysis
To determine percentage of cells positive for CD5, CD4, and
CD8 surface antigens, 30 ml of EDTA anti-coagulated blood was
added to 12675 mm polystyrene tubes, along with 0.15 mlo f
Alexa647-labeled anti-CD5, 0.15 ml of FITC-labeled anti-CD4,
and 0.3 ml of PE-labeled anti-CD8 mouse monoclonal antibodies
(Southern Biotech) diluted in FACS buffer (5% BSA, 0.1% sodium
azide in PBS). Anti-CD4 was directly labeled with FITC, anti-
CD8 to PE, and anti-CD5 was unlabeled but subsequently
conjugated to Alexa647 using a Zenon kit (Invitrogen). Samples
were incubated in the dark at room temperature with rocking for
30 min, washed 26, diluted to 100 mL with 16 PBS +2% BSA.
Next, red blood cells were lysed, and stained cells were fixed using
a Beckman Coulter Q-Prep work station with 600 ml of 0.1%
Formic Acid, 270 ml of 0.06 M Na2CO3 anhydrous, 0.25 M
NaCl, 0.25 M Na2SO3, and 90 ml 1% wt/vol paraformaldehyde
in 16PBS. Flow cytometry was performed on a CyAn cell sorter
(Dako Cytomation), and results analyzed using Summit software
package (Dako Cytomation). To determine complete leukocyte
and RBC counts from EDTA blood, a Z1 Series Coulter Counter
was used. Differential leukocyte counts were determined manually
from stained smears. Absolute neutrophil and lymphocyte counts
were calculated by multiplying the total leukocyte count by the
percentages of neutrophils or lymphocytes for each cat at each
time point. To determine absolute CD5
+, CD4
+ and CD8
+ cell
counts, total lymphocyte counts were multiplied by percentage of
Alexa647 (CD5), FITC (CD4), or PE (CD8) fluorescing cells.
Blood was collected from all cats prior to infection to establish
baseline values.
FIV proviral DNA and plasma RNA quantitation
Plasma was collected from EDTA-treated whole blood
following centrifugation and frozen at 270uC until processing.
RNA was purified from 140 ml of plasma using a QIAamp Viral
RNA Mini Kit (Qiagen). SuperscriptII (Invitrogen) was imple-
mented in reactions with random hexamers (Invitrogen) added,
and treated with RNase Out (Invitrogen) for preparation of cDNA
from viral RNA. Genomic DNA was extracted from PBMCs
purified on a Histopaque-1077 (Sigma, St. Louis, MO) gradient.
Cells were washed and pellets frozen at 220uC overnight. DNA
was isolated using a DNeasy Tissue Kit (Qiagen).
Real-time PCR reactions wererun using an iCycler thermocycler
(Bio-Rad) to detect both proviral and circulating FIV gag using the
AmpliTaq Gold DNA polymerase-containing TaqMan Universal
PCR Master Mix (Applied Biosystems). Sequences of primer/probe
(59FAM, 39TAMRA) sets are reported in [22] and were as follows:
FIV-A, f=GCCTTCTCTGCAAATTTAACACCT, r=GAT-
CATATTCTGTCAGTTGCTTT, and p=TGCGGCCATTAT-
TAATGTGGCCATG. FIV-C, f=ACTCACCCTCCTGATG-
GTC CTA, r=TGAGTCAGCCCTATCCCCATTA, and p=
ACCATTGCCATACTTCACTGC AGCCG. PCR reactions in a
total volume of 25 ml consisted of 12.5 ml master mix, 0.5 mle a c ho f
20 mM forward and reverse primers, 0.2 mlo f1 0mM probe, and
5 ml template. After 2 min at 50uC, the AmpliTaq Gold DNA
polymerase was activated at 95uC for 10 min, followed by 45 cycles
of 95uC for 15 s and 60uC for 1 min.
Threshold cycle values (CT) were defined as the point at which
the fluorescence passed a threshold limit. Copy number for FIV
provirus was calculated using a standard curve generated from
dilutions of a sub-cloned gag PCR product. To calculate copy
number of viral RNA in plasma, a standard curve was generated
by diluting FIV-PPR virus stock in naı ¨ve cat plasma; this was
prepared and analyzed by reverse-transcriptase quantitative PCR
as described above. CT values were compared to those of the sub-
cloned gag standard to assign values. Lower limits of detection
approached 10 RNA or DNA equivalents. Characteristics of
samples in this range included CT values over 40, higher standard
deviation between replicates, or detectable signal in only one or
two of three replicates.
Salivary viral RNA quantitation was similarly performed and is
described in detail in Supporting Information S1.
Statistics
To analyze decreases in CD5, CD4, and neutrophil counts, and
CD4:CD8 ratios for infection groups compared to controls at each
time point, GraphPad PrismH was used to determine one-tailed P
values in an unpaired t test. P values below 0.05 were considered
significant.
Supporting Information
Figure S1 Salivary viral loads from clade C FIV-C36,
and A/C chimeric FIV-PCenv infected cats. Group
averages with standard deviation relative to plasma viremia (A).
Pathogenicity of FIV Linked to 39 Elements
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e24020Trends for saliva and plasma RNA levels over time (B) presented
as RNA copies/ml. Mock-infected cats had undetectable viremia
(data not shown).
(TIF)
Supporting Information S1 Salivary viral RNA quantitation.
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